Literature DB >> 10518194

5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.

L Iyer1, M J Ratain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10518194     DOI： 10.3109/07357909909032859

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  9 in total

1.  Covalently mucoadhesive amphiphilic prodrug of 5-fluorouracil for enhanced permeation and improved oral absorption.

Authors:  Yan Liu; Dongyang Zhao; Mengchi Sun; Wei Wei; Yingli Wang; Jiahua Zhou; Ruoshi Zhang; Jian Wang; Haotian Zhang; Zhonggui He; Qiming Kan; Jin Sun
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

Review 2.  Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.

Authors:  J Andrew Skirvin; Stuart M Lichtman
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.

Authors:  R Goel; E Chouinard; D J Stewart; S Huan; H Hirte; S Stafford; B Waterfield; J Roach; C Lathia; V Agarwal; R Humphrey; W Walsh; S Matthews; L Seymour
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

4.  Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.

Authors:  B Glimelius; H Garmo; A Berglund; L A Fredriksson; M Berglund; H Kohnke; P Byström; H Sørbye; M Wadelius
Journal:  Pharmacogenomics J       Date:  2010-02-23       Impact factor: 3.550

5.  A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier.

Authors:  Man Li; Zhen Liang; Xun Sun; Tao Gong; Zhirong Zhang
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

6.  Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.

Authors:  Pei-Jian Peng; Hua Cheng; Xue-Qing Ou; Lin-Juan Zeng; Xuan Wu; Yu-Meng Liu; Zhong Lin; Yan-Na Tang; Si-Yang Wang; Hong-Yu Zhang; Zhi-Bin Chen
Journal:  Drug Des Devel Ther       Date:  2014-08-14       Impact factor: 4.162

7.  Targeted delivery of 5-fluorouracil-1-acetic acid (5-FA) to cancer cells overexpressing epithelial growth factor receptor (EGFR) using virus-like nanoparticles.

Authors:  Bee Koon Gan; Kamal Rullah; Chean Yeah Yong; Kok Lian Ho; Abdul Rahman Omar; Noorjahan Banu Alitheen; Wen Siang Tan
Journal:  Sci Rep       Date:  2020-10-08       Impact factor: 4.379

Review 8.  Pharmacological factors influencing anticancer drug selection in the elderly.

Authors:  Veena John; Sandeep Mashru; Stuart Lichtman
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

9.  Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.

Authors:  Sibylle Schirm; Christoph Engel; Sibylle Loibl; Markus Loeffler; Markus Scholz
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-04       Impact factor: 4.553
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.